Stryker Co. (NYSE:SYK) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. reduced its stake in shares of Stryker Co. (NYSE:SYK) by 0.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,425 shares of the medical technology company’s stock after selling 66 shares during the period. Advisors Asset Management Inc.’s holdings in Stryker were worth $10,234,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Thrivent Financial for Lutherans raised its holdings in Stryker by 3.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 96,868 shares of the medical technology company’s stock valued at $34,983,000 after acquiring an additional 3,629 shares during the last quarter. PDS Planning Inc boosted its position in Stryker by 9.8% in the 4th quarter. PDS Planning Inc now owns 1,562 shares of the medical technology company’s stock valued at $562,000 after buying an additional 140 shares during the period. RD Lewis Holdings Inc. purchased a new position in Stryker in the 4th quarter valued at approximately $285,000. Edgemoor Investment Advisors Inc. boosted its position in Stryker by 15.2% in the 4th quarter. Edgemoor Investment Advisors Inc. now owns 1,324 shares of the medical technology company’s stock valued at $477,000 after buying an additional 175 shares during the period. Finally, Flagship Wealth Advisors LLC purchased a new stake in shares of Stryker during the 4th quarter worth $119,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

NYSE SYK opened at $376.13 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $143.52 billion, a PE ratio of 48.47, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a 50 day moving average price of $383.71 and a two-hundred day moving average price of $373.82. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business earned $3.46 EPS. As a group, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Citigroup reiterated a “buy” rating and set a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.